Case 2
A 53-year-old woman presented with new onset acutely decompensated heart failure. An echocardiogram showed severe BiV failure with an LV ejection fraction of 10%. Right heart catheterization confirmed the diagnosis of cardiogenic shock despite dual inotropes and an intra-aortic balloon pump (Table) . Within 24 hours of admission, the patient developed MOSD. An Impella 5.0 device was deployed via the right femoral artery into the LV and a TandemHeart pump deployed to support RV function. Within 12 hours of BiV support, her hemodynamic parameters and MOSD improved, thereby permitting successful implantation of a surgical HeartWare BiVAD ( Figure 2 ). Pathological specimens confirmed extensive giant cell myocarditis. Within 3 months, the patient was discharged in stable condition and is currently awaiting transplantation. 
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Discussion
BiV failure is a primary determinant of poor outcomes in cardiogenic shock. 1 Persistent MOSD often complicates BiV failure and is a relative contraindication for surgical VAD placement. The use of percutaneous BiV support is relatively new. 3 No reports have described the combined use of an Impella 5.0 and TandemHeart pumps to support LV and RV function, respectively. Our report has several potentially important clinical implications. First, we identify the potential advantage of stabilizing hemodynamics and improving MOSD with percutaneous support instead of direct surgical BiVAD placement. As illustrated by case 1, despite improved hemodynamics, percutaneous support provided critical time for the patient's family to make an informed decision about surgical BiVAD placement. Second, we show that implantation of a percutaneous LV device may clarify the need for an right ventricular assist device by simulating the hemodynamic conditions when on LV support. In both cases, RV support was necessary despite LV support. Third, we demonstrate that BiV support may be achieved by either axillary or femoral deployment of an Impella 5.0 device with concomitant TandemHeart RV support. Finally, we demonstrate that stepwise evaluation of BiV function using hemodynamic variables may aid in determining the need for concomitant percutaneous RV support. In both cases, an elevated central venous pressure >16 mm Hg, right atrial:pulmonary capillary wedge pressure ratio >0.8, Pulmonary Artery Pulsatility Index <1.0, 4 and evidence of RV dilatation and impaired RV systolic function indicated the potential need for mechanical RV support. The clinical utility of these criteria after deployment of an LV support device has not been established and highlights the importance of examining all clinical variables when considering concomitant mechanical RV support. In conclusion, percutaneous circulatory support devices may serve as an additional therapeutic option for patients with BiV failure refractory to medical therapy. Further study is required to clarify the role of these device-based approaches for BiV failure. AST indicates aspartate aminotransferase; BP, blood pressure; CI, cardiac index; CVP, central venous pressure; IABP, intra-aortic balloon pump; PAP, pulmonary artery pressure; PAPI, pulmonary artery pulsatility index; PCWP, pulmonary capillary wedge pressure; RA, right atrial; RVAD, right ventricular assist device; and SVR, systemic vascular resistance.
